Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. It offers RYTELO a telomerase inhibitor for the treatment f adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia. The company was incorporated in 1990 and is headquartered in Foster City, California.
Analyst Outlook | Price targets range from $4 to $9, reflecting varied perspectives on Geron's future. The company's path to profitability remains a key focus for investors |
Expansion Potential | EU approval could boost Geron's global presence. Label expansion for Imetelstat, particularly in myelofibrosis, presents significant growth opportunities |
Market Challenges | Despite Q1 sales shortfall, Geron sees renewed growth. Analysts project profitability by 2H 2025, but inventory issues and competition pose risks |
Oncology Frontrunne | Geron's Rytelo shows promise in MDS and MF treatment, with consistent efficacy across patient groups and a favorable safety profile |
Metrics to compare | GERN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipGERNPeersSector | |
---|---|---|---|---|
P/E Ratio | −6.0x | −0.1x | −0.5x | |
PEG Ratio | −0.16 | 0.00 | 0.00 | |
Price / Book | 3.1x | 2.8x | 2.6x | |
Price / LTM Sales | 7.2x | 9.0x | 3.1x | |
Upside (Analyst Target) | 203.0% | 106.6% | 46.1% | |
Fair Value Upside | Unlock | 14.9% | 6.9% | Unlock |